新疫苗或能有效阻斷新冠變種感染
格隆匯7月27日丨美國加州大學聖地亞哥分校醫學院領導的一項新研究,描述了一種製造新冠疫苗的不同方法,這種疫苗在理論上對新出現的變種仍然有效,且可通過鼻吸、藥丸或其他方式接種。研究結果近日發表在《公共圖書館·病原體》在線期刊上。該研究涉及構建經過基因改造的質粒,包含一些專門針對新冠病毒刺突蛋白的脆弱性遺傳物質。刺突蛋白是病毒的一部分,對結合和感染細胞至關重要。而質粒是來自細菌的小的環狀DNA分子,它們在物理上與染色體DNA分離且可獨立複製。科學家可使用它們將遺傳物質從一個細胞轉移到另一個細胞,然後引入的遺傳物質就可在接收細胞中複製。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.